Last reviewed · How we verify
Influenza Trivalent Inactivated vaccines Novartis
Influenza Trivalent Inactivated vaccines Novartis is a Influenza vaccine Biologic drug developed by Novartis. It is currently in Phase 2 development for Influenza prevention.
Stimulates the body's immune response to the influenza virus
Stimulates the body's immune response to the influenza virus Used for Influenza prevention.
At a glance
| Generic name | Influenza Trivalent Inactivated vaccines Novartis |
|---|---|
| Sponsor | Novartis |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
This vaccine contains inactivated influenza viruses that stimulate the body's immune response, providing protection against the flu.
Approved indications
- Influenza prevention
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months (PHASE2)
- Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study (PHASE2)
- Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old (PHASE3)
- Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines (PHASE3)
- Comparison of 4 Influenza Vaccines in Seniors (PHASE4)
- Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza Trivalent Inactivated vaccines Novartis CI brief — competitive landscape report
- Influenza Trivalent Inactivated vaccines Novartis updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Influenza Trivalent Inactivated vaccines Novartis
What is Influenza Trivalent Inactivated vaccines Novartis?
How does Influenza Trivalent Inactivated vaccines Novartis work?
What is Influenza Trivalent Inactivated vaccines Novartis used for?
Who makes Influenza Trivalent Inactivated vaccines Novartis?
What drug class is Influenza Trivalent Inactivated vaccines Novartis in?
What development phase is Influenza Trivalent Inactivated vaccines Novartis in?
What are the side effects of Influenza Trivalent Inactivated vaccines Novartis?
Related
- Drug class: All Influenza vaccine drugs
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Influenza prevention
- Compare: Influenza Trivalent Inactivated vaccines Novartis vs similar drugs
- Pricing: Influenza Trivalent Inactivated vaccines Novartis cost, discount & access